Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab.

Revista espanola de enfermedades digestivas - 1 Nov 2023

Navajas Hernández Pilar, Del Pino Bellido Pilar, Lorenzo González Laura, González Rodríguez Concepción, Pérez Pérez Antonio, Argüelles Arias Federico

Abstract excerpt

BACKGROUND: the success of strategies with earlier anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) have been shadowed by the development of anti-drug antibodies that reduce their effectiveness. The HLA-DQA1*05 allele has been shown to increase the risk of immunogenicity to anti-TNF drugs by approximately two-fold. The negative impact of this allele has not been fully investigated for newer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Inflammatory Bowel Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37314124
DOI: 10.17235/reed.2023.9491/2023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab.PMID 37314124Read ↗

HLA-DQA1*05 Carriage is Associated with treatment failure and the induction of anti-IFX antibodies in IBD patientsSemantic proximity Read ↗

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Does HLA-DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small-bowel Crohn's disease?Semantic proximity Read ↗

Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD PatientsSemantic proximity Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.Semantic proximity Read ↗

Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.Semantic proximity Read ↗

Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.Semantic proximity Read ↗

HLA Class II Alleles are associated with Anti-Drug Antibodies in Ulcerative Colitis Patients Treated with EtrolizumabSemantic proximity Read ↗

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

HLA Class II Alleles Are Associated With Anti-Drug Antibodies in Ulcerative Colitis Patients Treated With Etrolizumab.Semantic proximity Read ↗

HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.